Cisplatin-based chemotherapy does not eliminate the risk of a second testicular cancer.
Of 781 patients with germ cell cancer, 14 developed a second (subsequent) testicular cancer during follow-up. The incidence was not related to the treatment of the first germ cell cancer. In particular, adequate cisplatin-based chemotherapy did not reduce the risk of developing a second tumour. Screening programmes in patients with previous germ cell tumours should include all patients, irrespective of prior treatment.